The anti-CTLA-4 antibody have a role in HCC treatment by increasing the expression of tumor-associated antigens, such as interleukin (IL)-1, IL-6 and macrophage inflammatory protein-1 [80,81,82]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.